-

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Metagenomi Inc. (MGX) Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) securities during the period from February 9, 2024 through May 1, 2024, inclusive (“the Class Period”). Investors have until November 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

[Click here to learn more about the class action]

On February 12, 2024, Metagenomi conducted its initial public offering (“IPO”), selling approximately 6.25 million shares at $15 per share. On May 1, 2024, less than two months after the IPO, Metagenomi announced that it and Moderna had “mutually agreed to terminate their collaboration.” On this news, the price of Metagenomi shares declined by $0.87, or 12.4%, from $7.04 per share on May 1, 2024, to close at $6.17 per share on May 2, 2024.

According to the lawsuit, Metagenomi’s statements in its IPO registration statement were false and/or materially misleading at the time of its IPO, which was conducted between February 9 and 13, 2024. Specifically, Metagenomi introduced itself to investors during its IPO as a “genetic medicines company” having a long-standing business relationship with Moderna, one of the leading Covid-19 vaccine companies. Contrary to these representations, Metagenomi’s collaboration with Moderna would not extend into the future but instead terminate in the immediate future.

If you purchased or otherwise acquired Metagenomi securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:MGX

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos...

IBRX ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your ImmunityBio investments, you have until May 26, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERE...

PYPL DEADLINE NOTICE: PayPal Holdings, Inc. Investors Encouraged to Contact Kirby McInerney LLP By April 20, 2026

NEW YORK--(BUSINESS WIRE)--If you suffered a loss on your investment inPayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ:PYPL), contact Lauren Molinaro by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 20, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff ove...
Back to Newsroom